Sucralfate for Prevention of Naproxen-induced Mucosal Lesions in the Proximal and Distal Gastrointestinal Tract

References

• Somerville K, Gail Faulkner, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet 1986; i: 462–4
   Google Scholar
• Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic ulcer disease. N Engl J Med 1974; 290: 1158–62
   PubMed Web of Science ®Google Scholar
• Duggan J M, Dobson A J, Johnson H, Fahey P. Peptic ulcer and non-steroidal anti-inflammatory agents. Gut 1986; 27: 929–33
   PubMed Web of Science ®Google Scholar
• Nagaraj H S, Sandhu A S, Cook L N, Buchino J J, Groff DB. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg 1981; 166: 1003–7
   Google Scholar
• Langman M JS, Morgan L, Worrell A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J 1985; 290: 347–9
   PubMed Web of Science ®Google Scholar
• Madhok R, Mackenzie A, Lee FD. Small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs for rheumatoid arthritis. Quart J Med 1986; 255: 53–8
   Google Scholar
• Rampton DS. Non-steroidal anti-inflammatory drugs and the lower gastrointestinal tract. Scand J Gastroenterol 1987; 22: 1–4
   PubMed Web of Science ®Google Scholar
• CSM Update. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions—2. Br Med J 1986; 292: 1190–1
   PubMed Web of Science ®Google Scholar
• Bijlsma J WJ. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: An international multicentre collaborative study. Aliment Pharmacol Ther 1988; 2S: 85–96
   Google Scholar
• Roth S H, Bennett R E, Mitchell C S, Hartman RJ. Cimetidine therapy in nonsteroidal antiinflammatory drug gastropathy. Arch Intern Med 1987; 147: 1798–1801
   PubMedGoogle Scholar
• Aabakken L, Larsen S, Osnes M. Gastrointestinal side-effects of naproxen: Are they reduced by cimetidine tablets or suspension? (abstract). Scand J Gastroenterol 1987; 22: 59, suppl 135
   PubMedGoogle Scholar
• Kauffman G L, Foley K T, Grossman MI. Cimetidine does not inhibit Indomethacin-induced small bowel ulceration in the rat. Proc Soc Exp Biol Med 1979; 161: 512–4
   PubMedGoogle Scholar
• Lanza F L, Aspinall R L, Swabb EA. Double blind placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroenterology 1988; 95(2)289
   PubMed Web of Science ®Google Scholar
• Aadland E, Fausa O, Vatn M. Protection by Misoprostol against Naproxen-induced mucosal damage. Am J Med 1987; 83: 37–40, suppl 1A
   PubMedGoogle Scholar
• Bjarnason I, Smethurst P, Fenn G C, Lee C E, Levi AJ. Misoprostol reduces indomethacin induced changes in human small intestinal permeability. Gastroenterology 1988; part 2(5)94, A37
   Google Scholar
• Hawkey C J, Walt RP. Prostaglandins for peptic ulcer: A promise unfulfilled. Lancet 1986; ii: 1084–6
   Google Scholar
• Hollander D. Efficacy of Sucralfate for duodenal ulcers; a multicenter double-blind trial. J Clin Gastroenterol 1981; 3: 153–7, suppl 2
   PubMedGoogle Scholar
• Lam S K, Lau W Y, Lai CL. Efficacy of Sucralfate in corpus, prepyloric, and duodenal ulcer-associated gastric ulcers. Am J Med 1985; 79: 24–31, suppl 2c
   PubMed Web of Science ®Google Scholar
• Martin F, Farley M, Gagnon MK. Short-term treatment with Sucralfate or Cimetidine in gastric ulcer: Preliminary results of a controlled randomized trial. Scand J Gastroenterol 1983; 18: 37–41, suppl 83
   Web of Science ®Google Scholar
• Hentschel E, Schutzke K, Dufer W. Controlled comparison of Sucralfate and Cimetidine in duodenal ulcer. Scand J Gastroenterol 1983; 18: 31–5, suppl 83
   Web of Science ®Google Scholar
• Stern A I, Ward F, Hartley G. Protective effect of Sucralfate against Aspirin-induced damage to the human gastric mucosa. Am J Med 1987; 83(suppl 3B)83–5
   PubMedGoogle Scholar
• Caldwell J R, Roth S H, Wu W, Heller M D, Marsh WH. Sucralfate treatment of non-steroidal antiinflammatory drug-induced gastrointestinal symptoms and damage. Am J Med 1987; 83(3 B)74–82
   PubMedGoogle Scholar
• Manniche C, Malchow-Møller A, Andersen J R, Pedersen C, Hansen TM, Jess P, Helleberg L, Rasmussen S N, Tage-Jensen U, Nielsen SE. Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut 1987; 28: 226–9
   PubMed Web of Science ®Google Scholar
• Stiel D, Ellard K T, Hills L J, Brooks PM. Protective effect of enprostil against aspirin-induced gastroduodenal mucosal injury in man. Comparison with Cimetidine and Sucralfate. Am J Med 1986; 81(2A)54–8
   PubMedGoogle Scholar
• Bjarnason I, Peters TJ. A persistent defect in intestinal permeability in coeliac disease demonstrated by a Cr-labelled EDTA absorption test. Lancet 1983; i: 323–5
   Google Scholar
• Aabakken L, Bjørnbeth B A, Hofstad B, Olaussen B, Larsen L, Osnes M. Comparison of the gastrointestinal side effects of Naproxen formulated as plain tablets, enteric coated tablets or enteric coated granules in capsules. Scand J Gastroenterol 1989; 24: 65–73, suppl 163
   PubMed Web of Science ®Google Scholar
• Robert A. Cytoprotection by Prostaglandins. Gastroenterology 1979; 77: 761–7
   PubMed Web of Science ®Google Scholar
• Nagashima R. Mechanisms of action of sucralfate. J Clin Gastroenterol 1981; 3: 117–27, suppl 2
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism for aspirin-like drugs. Nature New Biol 1971; 281: 232–5
   Google Scholar
• Kivilaakso E, Silen W. Pathogenesis of experimental gastromucosal injury. N Engl J Med 1979; 301: 362–9
   Google Scholar
• Cooke AR. Gastric damage by drugs and the role of the mucosal barrier. Aust NZ J Med 1976; 23–6
   PubMedGoogle Scholar
• Caille G, du Souich P, Gervais P, Besner J G, Vezina M. Effects of concurrent sucralfate administration on pharmacokinetics of naproxen. Am J Med 1987; 83(3B)67–73
   PubMedGoogle Scholar
• Bjarnason I, Williams P, Smethurst P, Peters T J, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292–7
   PubMed Web of Science ®Google Scholar
• Auer I O, Habscheid W, Hiller S, Gerhards W, Eilles C. Nicht-steroidal Antiphlogistika erhdhen die Darm-permeabilität. Dtsch Med Wschr 1987; 112: 1032–7
   PubMedGoogle Scholar
• Bjarnason I, Prouse P, Smith T, Gumpel M J, Zanelli G., Smethurst P, Levi S, Levi AJ. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; ii: 7111
   Google Scholar
• Bjarnason I, O'Morain C, Levi A J, Peters TJ. Absorption of 51-chromium-labeled ethylene-diamine-tetraacetate in inflammatory bowel disease. Gastroenterology 1983; 85: 318–22
   PubMed Web of Science ®Google Scholar
• Jenkins R T, Jones D B, Goodacre R L, Collins S M, Coates G, Hunt R H, Bienenstock J. Reversibility of increased intestinal permeability to 51Cr-EDTA in patients with gastrointestinal inflammatory diseases. Am J Gastroenterol 1987; 82(11)1159–64
   PubMedGoogle Scholar
• Aabakken L. 51Cr-EDTA absorption test: Evaluation of its validity. Scand J Gastroenterol 1989; 24: 351–8
   PubMed Web of Science ®Google Scholar
• Mellem H, Stave R, Myren J, Osnes M, Hanssen L E, Mosvold J, Hebnes K. Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid antiinflammatory drugs. Scand J Gastroenterol 1985; 20: 1246–8
   PubMed Web of Science ®Google Scholar